Skip to main content Accessibility help
×
Home
Hostname: page-component-65dc7cd545-nrv4r Total loading time: 0.182 Render date: 2021-07-25T03:49:00.593Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

EPA-1586 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Clinical Outcome

Published online by Cambridge University Press:  15 April 2020

B. Leitner
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
E. Weidinger
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
S. Fischer
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
D. Krause
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
A.M. Myint
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
P. Zill
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
M.J. Schwarz
Affiliation:
Department of Laboratory Medicine, Ludwig-Maximilians-University, München, Germany
N. Müller
Affiliation:
Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, München, Germany
Get access

Abstract

Introduction

A proinflammatory state in a subgroup of depressed patients has been reported repeatedly, for example an increase in interleukin-6 and tumour necrosis factor-a is well documented. Treatment with COX-2 inhibitors down-regulate increased inflammatory markers. Therefore an adjunctive treatment of depression with COX-2 in combination with an antidepressant might lead to a better clinical outcome.

Objectives

To prove or disapprove the hypothesis of a better clinical outcome in the group with add-on celecoxib to sertraline in terms of improvement of HamD-17 and MADRS scores from baseline to endpoint.

Design

This is a dual-center, randomized, double-blind, placebo-controlled, parallel group phase IIa study to investigate the mean change in clinical outcome and in serum expression of inflammation markers from baseline to endpoint (week 6) in patients with major depression (HAMD-17 ≥ 22) treated with celecoxib in combination with sertraline compared to sertraline combined with placebo. 51 depressed patients of both gender, aged between 18 and 60 without any recent inflammatory related disease were enrolled. The study comprises six study visits (6x ratings including HAMD-17 and MADRS, 3x blood collections) during six weeks of treatment and a follow-up visit 10 weeks after baseline.

Results and Conclusion

The study was completed quite recently and the results are in progress.

Type
P08 - Depression
Copyright
Copyright © European Psychiatric Association 2014

Access options

Get access to the full version of this content by using one of the access options below.
Submit a response

Comments

No Comments have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

EPA-1586 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Clinical Outcome
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

EPA-1586 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Clinical Outcome
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

EPA-1586 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Clinical Outcome
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *